BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
How federal officials talk about health is shifting in troubling ways – and that change makes me worried for my autistic child - 2Tire Brands for Senior Drivers: Guaranteeing Security and Solace
- 3Figure out How to Get a good deal on Your Rooftop Substitution Venture
- 4Investigate These Retreats Well known With Seniors
- 5A hospital discharged a woman in labor. This lawmaker wants change.
- More parents refusing vitamin K shots for newborns, study finds
- Melodic Event: A Survey of \Energies and Exhibitions Assessed\ Live concert
- Germany expresses 'great concern' over Israel's new death penalty law
- Instructions to Keep up with Your Traded Teeth for Life span
- 6 Arranging Administrations to Change Your Open air Space
- Why the weirdest sea level changes on Earth are happening off the coast of Japan
- Step by step instructions to Protect Your Senior Condo for Ideal Wellbeing and Solace
- Internet goes (cocoa) nuts: The funniest reactions to 12 tonne theft of KitKat bars
- Lilly, Novo lock horns in India's obesity drug race
